CHICAGO, Illinois — A genetic change or variant in a gene called SCN2A is a known cause of infantile seizures, autism spectrum disorder and intellectual disability, as well as a wide range of other moderate-to-profound impairments in mobility, communication, eating and vision. The severity of these disorders can vary widely...
Latest News
South Bend, Indiana – Certain types of light have proven to be an effective, minimally invasive treatment for cancers located on or near the skin when combined with a light-activated drug. But deep-seated cancers, surrounded by tissue, blood and bone, have been beyond the reach of light’s therapeutic effects. To...
South Bend, Indiana – Researchers at the University of Notre Dame have developed a novel, automated device capable of diagnosing glioblastoma, a fast-growing and incurable brain cancer, in less than an hour. The average glioblastoma patient survives 12-18 months after diagnosis. The crux of the diagnostic is a biochip that...
South Bend, Indiana – What could cancer teach us about tuberculosis? That’s a question Meenal Datta has been chasing since she was a graduate student. Once the body’s immune system is infected with tuberculosis, it forms granulomas — tight clusters of white blood cells — in an attempt to wall...
Notre Dame’s famous “Touchdown Jesus” mural lit up for Rare Disease Day on Tuesday.
Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of cancer, especially colorectal and endometrial, to as high as 80% NOUS-209 is an off-the-shelf immunotherapy designed to harness the power of the immune system to recognize and eliminate cancer cells before tumors develop Final...
BASEL, Switzerland – Nouscom, a clinical-stage biotech company developing next-generation off-the-shelf and personalized neoantigen cancer immunotherapies, today announced the presentation of new clinical and translational data on its lead candidate NOUS-209 at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting. Following positive safety and immunogenicity data reported at...
FALLS CHURCH, Va. – This year, nearly 2 million Americans will be diagnosed with cancer. But one-quarter won’t fill their expensive prescriptions, and another 20% will ration their drugs due to cost – which can total $15,000 per month or more. But thanks to a partnership between NOVA ScriptsCentral and...
Mont Saint-Guibert and Brussels, Belgium – Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, and the Cliniques universitaires Saint-Luc today announce the successful treatment of four pediatric patients with Congenital Pseudarthrosis of the Tibia (CPT) using NVD003, an autologous therapy developed by Novadip for the reconstruction of...
Authorization to start clinical trial in the US granted for rare paediatric bone disease Mont-Saint-Guibert – Novadip Biosciences (“Novadip”), a clinical stage company developing treatments to regenerate impaired tissues in patients with significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s...